◀ Back to MTOR
GSK3B — MTOR
Pathways - manually collected, often from reviews:
Protein-Protein interactions - manually collected from original source literature:
Studies that report less than 10 interactions are marked with *
Text-mined interactions from Literome
Li et al., Int J Biochem Cell Biol 2005
(MAP Kinase Signaling System) :
Here we tested the hypothesis that PI3K/Akt mediated inactivation of
GSK-3beta and
activation of
mTOR contribute to the anabolic effects of IGF-I in dexamethasone treated myotubes ... Our results suggest that PI3K/Akt mediated inactivation of
GSK-3beta and
activation of
mTOR contribute to the anabolic effects of IGF-I in dexamethasone treated myotubes
Chanoit et al., Am J Physiol Heart Circ Physiol 2008
(Myocardial Reperfusion Injury) :
The effect of zinc on
GSK-3beta activity was
blocked by the phosphatidylinositol 3-kinase (PI3K) inhibitor LY-294002 but not by the
mammalian target of rapamycin (mTOR) inhibitor rapamycin or the PKC inhibitor chelerythrine, implying that PI3K but not mTOR or PKC accounts for the action of zinc
Mariappan et al., J Biol Chem 2008
(Diabetes Mellitus, Type 2...) :
Incubation with selective kinase inhibitors showed that high glucose- and high insulin induced laminin beta1 synthesis and phosphorylation of
GSK3beta were
dependent on PI 3-kinase, Erk, and
mTOR